Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Sujan Kabir"'
Autor:
Firas El Chaer, Lindsay Rein, Kazuya Shimoda, Junichiro Yuda, Tamanna Haque, James Mccloskey, Akiyoshi Takami, Masafumi Fukaya, Shuichi Shirane, Sujan Kabir, Jian Mei, Zhonggai LI, Mark Wade, Claudia Lebedinsky, Raajit K Rampal
Publikováno v:
HemaSphere, Vol 7, p e42358df (2023)
Externí odkaz:
https://doaj.org/article/ef0764327e2144cb9246525a9d8831ba
Publikováno v:
Clinical lymphoma, myelomaleukemia. 22
Ruxolitinib, the standard treatment for patients with myelofibrosis to reduce splenomegaly and improve myelofibrosis-associated symptoms, is associated with high rates of cytopenia effect. Thrombocytopenia, common in myelofibrosis patients, is associ
Autor:
Firas El Chaer, James McCloskey, Lindsay A.M. Rein, Randy A. Brown, Steven D. Green, Jeffrey J. Pu, Shuichi Shirane, Kazuya Shimoda, Michiko Ichii, Junichiro Yuda, Joseph Scandura, Sujan Kabir, Jason M Foulks, Jian Mei, Huyuan Yang, Mark Wade, Carl Stapinski, Claudia Lebedinsky, Raajit K Rampal
Publikováno v:
Blood. 140:594-595
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S159
Autor:
Geeti Gangal, Sonke Svenson, Chester A. Metcalf, Pochi Shum, Snehlata Tripathi, Jungyeon Hwang, Stephanie Harlfinger, Beata Sweryda-Krawiec, Roy I. Case, Douglas Lazarus, Derek van der Poll, Sujan Kabir, Donna Brown, Ellen Rohde, Chi-Hse Teng, Roderic O. Cole, Scott Eliasof
Publikováno v:
Journal of Medicinal Chemistry. 62:9541-9559
Novel nanoparticle-drug conjugates (NDCs) containing diverse, clinically relevant anticancer drug payloads (docetaxel, cabazitaxel, and gemcitabine) were successfully generated and tested in drug discovery studies. The NDCs utilized structurally vari
Autor:
Huyuan Yang, Edgar Braendle, Jian Mei, Claudia Lebedinsky, Golam Mohi, Steven L. Warner, Sujan Kabir
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S355-S356
Context: MF is characterized by bone marrow fibrosis (BMF), ineffective hematopoiesis, splenomegaly, and debilitating symptoms. Expression of PIM-1 is significantly upregulated in MF hematopoietic cells, indicating that PIM-1 is a potential therapeut
Autor:
Ignacio Garrido-Laguna, Patrick M. Dillon, Sujan Kabir, Jian Mei, Mark L. Wade, Huyuan Yang, Carl Stapinski, Jason M. Foulks, Steven L. Warner, Clifford Whatcott, Claudia Lebedinsky, Siqing Fu
Publikováno v:
Molecular Cancer Therapeutics. 20:P223-P223
Background: Elevated expression of PIM kinases in various solid and hematologic malignancies is correlated with increased cell survival and reduced apoptosis, implicating inhibition of PIM kinases as attractive targets for disruptive therapy. TP-3654
Autor:
Claudia Lebedinsky, Sujan Kabir, Steven Warner, Golam Mohi, Huyuan Yang, Jian Mei, Edgar Braendle
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S235
Autor:
Pei-Sze Ng, Patrick Lim Soo, Sonke Svenson, Snehlata Tripathi, Roy I. Case, Sujan Kabir, Douglas Lazarus, Pochi Shum, Roderick O. Cole, Derek van der Poll, Jungyeon Hwang, Scott Eliasof, Beata Sweryda-Krawiec, Christian G. Peters
Publikováno v:
Molecular Pharmaceutics. 13:737-747
Small interfering RNA (siRNA) therapeutics have potential advantages over traditional small molecule drugs such as high specificity and the ability to inhibit otherwise "undruggable" targets. However, siRNAs have short plasma half-lives in vivo, can
Autor:
Moshe Talpaz, James Shao, Claire N. Harrison, John Mascarenhas, Jennifer A. Mertz, Srdan Verstovsek, Marina Kremyanskaya, Patrick Trojer, Prithviraj Bose, Sujan Kabir, Brian Leber, Shireen Sirhan, Adrian M. Senderowicz, Ronald Hoffman, Vikas Gupta
Publikováno v:
Blood. 134:670-670
Background: CPI-0610, a selective and potent small molecule BETi, has shown clinical activity and a wide therapeutic window in a Phase 1 lymphoma study (Blum KA, 2018). BET proteins regulate key oncogenic pathways, including NFκB and TGFβ signaling